We have located links that may give you full text access.
Safety issues relating to the use of mammalian cells as hosts.
There has been increasing interest over the past decade in exploring the possibility of using continuous cell lines as substrates for the production of both old and new biological products. The recent introduction of hybridoma technology to produce monoclonal antibodies, and the use of lymphoblastoid cells to produce interferon has broadened the discussion even further because both of those cell substrates are frankly tumorigenic. More recently, recombinant DNA technology has expanded beyond bacterial cells to mammalian cells, some of which may also be tumorigenic. One of the major safety concerns in biologicals produced from other than normal cells relates to the possibility that one or more of the biological characteristics of abnormal cells might be transmitted through residual DNA in the biological product to the human recipients. The assessment of risk for a given product must ultimately be based on the totality of evidence available including generic data on DNA as well as specific pieces of information on the product itself. These issues are discussed in the context of attempting to identify those data elements for the product which are essential for making an assessment of risk, plus generic information which may help to put the risk of DNA into an overall biological perspective.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app